SLCO1B1521T>C和388A>G基因多态性对冠心病患者阿托伐他汀降脂疗效的影响  

Influence of SLCO1B1521T>C and 388A>G gene polymorphism on the lipid-lowering effect of atorvastatin in patients with coronary heart disease

作　　者：白颖[1] 史旭波[2] 王建旗[2] 杨毅[2] 葛兴[2] 张弨 BAI Ying;SHI Xu-bo;WANG Jian-qi;YANG Yi;GE Xing;ZHANG Chao(Department of Pharmacy,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China;Cardiovascular Center,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院药学部,北京100730 [2]首都医科大学附属北京同仁医院心血管中心,北京100730

出　　处：《中国药物应用与监测》2021年第3期143-146,共4页Chinese Journal of Drug Application and Monitoring

基　　金：首都卫生发展科研专项(2016-2-2072)。

摘　　要：目的:探讨SLCO1B1521T>C和388A>G基因多态性对冠状动脉粥样硬化性心脏病患者应用阿托伐他汀降脂疗效的影响,为临床合理用药提供参考。方法:纳入2017年11月-2018年8月就诊于我院的冠心病患者,给予阿托伐他汀钙20 mg·d^(-1),服用12周。测定患者用药前及用药12周后的血脂水平,包括总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)。用Sanger法检测SLCO1B1521T>C(rs4149056)和388A>G(rs2306283)基因多态性。结果:研究共纳入80例冠心病患者,SLCO1B1521T>C和338A>G基因多态性的等位基因频率分别为11.25%和76.87%。阿托伐他汀治疗12周后,TG、TC、LDL-C水平较治疗前下降(P<0.05),而HDL-C水平无显著性差异(P=0.263)。TT基因型与(TC+CC)基因型相比,患者血脂水平变化率无显著性差异(P>0.05),GG基因型与(AA+AG)基因型相比,患者血脂水平变化率无显著性差异(P>0.05)。结论:SLCO1B1521T>C和388A>G基因多态性对阿托伐他汀降脂疗效无显著影响,本研究为探究SLCO1B1多态性对阿托伐他汀降脂疗效的影响提供了参考。Objective:To investigate the influence of SLCO1B1521T>C and 388A>G gene polymorphism on the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease and provide references for clinical use of atorvastatin.Methods:Patients with coronary heart disease in our hospital from November 2017 to August 2018 were recruited in this study and were treated with atorvastatin 20 mg·d^(-1) for 12 weeks.The serum lipid parameters,including total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)were measured before and after atorvastatin therapy.SLCO1B1521T>C(rs4149056)and 388A>G(rs2306283)gene polymorphism was detected by Sanger sequencing method.Results:A total of eighty patients with coronary heart disease were enrolled.The allele frequencies of the SLCO1B1521T>C and 338A>G polymorphism were 11.25%and 76.87%respectively.After 12 weeks of atorvastatin treatment,the levels of TG,TC,LDL-C significantly decreased(P<0.05),while the level of HDL-C was not significantly different from the baseline before treatment(P=0.263).There was no significant difference in lipid levels between TT genotype and(TC+CC)genotype(P>0.05)and the same results were observed between GG genotype and(AA+AG)genotype(P>0.05).Conclusion:SLCO1B1521T>C and 388A>G gene polymorphism showed no significant influence on the lipid-lowering effect of atorvastatin.This study provided a reference for exploring the effect of SLCO1B1 polymorphism on the lipid-lowering efficacy of atorvastatin.

关 键 词：阿托伐他汀 SLCO1B1 基因多态性 降脂疗效 

分 类 号：R969.4[医药卫生—药理学] R972.6[医药卫生—药学]